Propofol vs. remimazolam besilate for the prevention of postoperative nausea and vomiting.

Propofol vs. remimazolam besilate for the prevention of postoperative nausea and vomiting. - Propofol vs. remimazolam besilate for the prevention of postoperative nausea and vomiting.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039367

Enrollment

Registered

2020-04-01

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients undergoing laparoscopic gynecologic surgery

Interventions

Maintain anesthesia with propofol. Maintain anesthesia with remimazolam besilate.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Eligible patients meet the criteria of the American Society of Anesthesiologists(ASA) physical status of I-III.

Exclusion criteria

Exclusion criteria: Eligible patients meet the criteria of the American Society of Anesthesiologists(ASA) physical status of IV-V. Patients without consent. Pregnant woman.

Design outcomes

Primary

Measure	Time frame
frequency of the postoperative nausea and vomiting	—

Countries

Japan

Contacts

Public ContactNami Kakuta

Tokushima University Hospital Anesthesiology

kakuta.nami@tokushima-u.ac.jp088-633-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026